Ariana Pelosci

A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.

Updated results from the POSITIVE trial found that patients younger than 35 years had a higher likelihood of achieving pregnancy during an endocrine therapy pause for HR-positive breast cancer.

Disease-free survival did not show statistical significance for patients with early-stage non–small cell lung cancer treated with durvalumab.

Data from the colorectal cancer cohort of the KRYSTAL-1 trial support the accelerated approval of adagrasib/cetuximab in KRAS G12C–mutated disease.

Joleen Hubbard, MD, explains why allowing access to results can improve patient’s outlook on treatments and understanding of their disease.

Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.

A cohort study of the KarMMa-2 trial found durable responses in patients with high-risk multiple myeloma treated with ide-cel.

Phase 3 data from the E1910 trial support the FDA approval of blinatumomab in CD19-positive Philadelphia chromosome–negative B-cell precursor ALL.

TRANSCEND NHL 001 subgroup analysis found that liso-cel may be more effective for patients with mantle cell lymphoma in earlier lines of treatment.

Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.

Cathy Bradley, PhD, and Lindsay M. Sabik, PhD, spoke about moving the needle forward in the public health space through research and persistence.

Data from the EPCORE NHL-1 trial support the safety and feasibility of epcoritamab for patients with relapsed/refractory follicular lymphoma.

Final DFS results from IMpower010 show consistent survival when adjuvant atezolizumab was used in stage IB to IIIA NSCLC.

Giving tocilizumab before step-up dosing of teclistamab may mitigate cytokine release syndrome in relapsed/refractory multiple myeloma.

Responses occurred in patients with relapsed/refractory multiple myeloma who are refractory to daratumumab but received retreatment with the agent.

A survival benefit was observed when nivolumab and ipilimumab were combined to treat ovarian or gynecologic clear cell carcinoma.

The CARACO study shows that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

The CheckMate -901 trial led to the approval of the nivolumab combination for unresectable or metastatic urothelial carcinoma in the European Union.

The 5-year follow-up results from CheckMate 040 showed consistent responses with nivolumab/ipilimumab in advanced hepatocellular carcinoma.

Tiffany A. Traina, MD, FASCO, and Sherry Shen, MD, share their personal and professional journeys to becoming breast oncologists at Memorial Sloan Kettering Cancer Center.

Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.

Patients with BRCA-mutated breast cancer can safely undergo assisted reproductive techniques, according to an ESMO study.

Metformin, a type 2 diabetes drug, was found to reduce myeloproliferative neoplasm development.

Fumiko Chino, MD, discusses how recent findings of talcum powder use were linked to ovarian cancer.

Nivolumab plus ipilimumab has shown a response benefit when given at an increased dose for those with metastatic urothelial carcinoma.

The NEOpredict-Lung trial met its primary end point with nivolumab plus relatlimab for patients with resectable non–small cell lung cancer.

Neil M. Iyengar, MD, spoke about the importance of exercise oncology and how it may play a role in positive treatment outcomes for breast cancer.

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

Results of the Sister Study cohort found an increased risk of ovarian cancer when enrolled patients used genital talcum powder throughout young adulthood.

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.